trending Market Intelligence /marketintelligence/en/news-insights/trending/uqmjxg4wd9_tuttispm5dq2 content esgSubNav
In This List

IDT Australia receives warning letter from US FDA

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


IDT Australia receives warning letter from US FDA

IDT Australia Ltd. said it received a warning letter from the U.S. Food and Drug Administration regarding a December 2017 audit of its facilities.

The FDA raised concerns regarding investigations of out of specification results and deviations, plus the ability of IDT's quality system to ensure data integrity to support manufacture of its products.

The company said it has made changes including recruitment of quality and operational personnel and that it is implementing remedies that will fully address the FDA's concerns.

Australia-based IDT Australia develops and sells active pharmaceutical ingredients and finished drug products worldwide.